Abstract:Objective: The management of patients with aneurysmal subarachnoid hemorrhage (aSAH) remains a highly demanding challenge in critical care medicine. Despite all efforts, the calcium channel antagonist nimodipine remains the only drug approved for improving outcomes after aSAH. However, in its current form of application, it provides less than optimal efficacy and causes dose-limiting hypotension in a substantial number of patients. Here, the authors tested in vitro the release dynamics of a novel formulation of the calcium channel blocker nicardipine and in vivo local tolerance and tissue reaction using a chronic cranial window model in mice. Methods: To characterize the release kinetics in vitro, dissolution experiments were performed using artificial cerebrospinal fluid over a time period of 21 days. The excipients used in this formulation (NicaPlant) for sustained nicardipine release are a mixture of two completely degradable polymers. A chronic cranial window in C57BL/6 mice was prepared, and NicaPlant slices were placed in proximity to the exposed cerebral vasculature. Epifluorescence video microscopy was performed right after implantation and on days 3 and 7 after surgery. Vessel diameter of the arteries and veins, vessel permeability, vessel configuration, and leukocyte-endothelial cell interaction were quantified by computer-assisted analysis. Immunofluorescence staining was performed to analyze inflammatory reactions and neuronal alterations. Results: In vitro the nicardipine release profile showed an almost linear curve with about 80% release at day 15 and full release at day 21. In vivo epifluorescence video microscopy showed a significantly higher arterial vessel diameter in the NicaPlant group due to vessel dilatation (21.6 ± 2.6 µm vs 17.8 ± 1.5 µm in controls, p < 0.01) confirming vasoactivity of the implant, whereas the venous diameter was not affected. Vessel dilatation did not have any influence on the vessel permeability measured by contrast extravasation of the fluorescent dye in epifluorescence microscopy. Further, an increased leukocyte-endothelial cell interaction due to the implant could not be detected. Histological analysis did not show any microglial activation or accumulation. No structural neuronal changes were observed. Conclusions: NicaPlant provides continuous in vitro release of nicardipine over a 3-week observation period. In vivo testing confirmed vasoactivity and lack of toxicity. The local application of this novel nicardipine delivery system to the subarachnoid space is a promising tool to improve patient outcomes while avoiding systemic side effects.

Anti-Neuroinflammatory Effects of the Calcium Channel Blocker Nicardipine on Microglial Cells: Implications for Neuroprotection

Brain Microglial Cytokines in Neurogenic Hypertension

Nimodipine Protects Dopaminergic Neurons Against Inflammation-Mediated Degeneration Through Inhibition of Microglial Activation

Nimodipine reduces microglial activation in vitro as evidenced by morphological phenotype, phagocytic activity and next generation RNA sequencing

Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats.

Combined NADPH and the NOX Inhibitor Apocynin Provides Greater Anti-Inflammatory and Neuroprotective Effects in a Mouse Model of Stroke

Combined Nadph And The Nox Inhibitor Apocynin Provides Greater Anti-Inflammatory And Neuroprotective Effects In A Mouse Model Of Stroke (Vol 104, Pg 333, 2017)

The potential use of nicardipine in cerebrovascular disease

Nicotine Induced Neurocognitive Protection and Anti-inflammation Effect by Activating 42 Nicotinic Acetylcholine Receptors in Ischemic Rats

Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking

Effect of nifedipine, a calcium channel blocker, on the generation of nitric oxide and interleukin-1β by murine macrophages activated by lipopolysaccharide from Prevotella intermedia

Nicorandil protects against coronary microembolization-induced myocardial injury by suppressing cardiomyocyte pyroptosis via the AMPK/TXNIP/NLRP3 signaling pathway

L-Type Ca2+ Channel Inhibition Rescues the LPS-Induced Neuroinflammatory Response and Impairments in Spatial Memory and Dendritic Spine Formation

NAD+ Blocks H2O2‐induced HMGB1 Translocation of PC12 Cells and Decreases Survival of Microglia

Nicotine induced neurocognitive protection and anti-inflammation effect by activating α4β2 nAChRs in ischemic rats.

In vitro and in vivo testing of a novel local nicardipine delivery system to the brain: a preclinical study

NNC 26-9100 increases Aβ1-42 phagocytosis, inhibits nitric oxide production and decreases calcium in BV2 microglia cells

Intravenous Injection of Nicardipine Changed the Distribution of Coronary Artery Endothelial Shear Stress and Fluid Dynamics in Patients with Unstable Angina.

Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-κB and JNK/p38 MAPK pathways

Nicotinamide riboside rescues angiotensin --induced cerebral small vessel disease in mice.

Nicotine-Induced Neuroprotection Against Ischemic Injury Involves Activation of Endocannabinoid System in Rats